Sunday, January 6, 2013

NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D) (NASDAQ:VRTX)

NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D) (NASDAQ:VRTX)
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)